[Form 4] ADMA BIOLOGICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Adam S. Grossman, President & CEO and director of ADMA BIOLOGICS (ADMA), reported multiple transactions on 09/15/2025 under a previously disclosed Rule 10b5-1 plan. He exercised a stock option to acquire 15,000 shares at an exercise price of $5.40 and sold a total of 21,000 shares (15,000 and 6,000) at $16.13. After these transactions he directly owned 2,025,850 shares and indirectly controlled an additional 1,724,383 shares through Areth, LLC and Hariden, LLC. The option exercised was originally granted on 02/26/2024 and vests through 02/26/2028. The reporting person also holds unvested RSUs totaling 1,033,966 across grants from 2022–2025 that will settle into common stock upon vesting.

Insights

Financial Analyst

TL;DR: Insider used a pre-existing 10b5-1 plan to exercise options and reduce holdings via sales while keeping a large ownership stake.

The filing shows routine, pre-planned activity rather than opportunistic trading: a 15,000-share option exercise at $5.40 and sales of 21,000 shares at $16.13 executed under a 10b5-1 plan. The CEO retains substantial direct ownership (2,025,850 shares) plus indirect control of 1,724,383 shares, and holds material unvested RSUs and an option pool. For investors, this indicates continued alignment with company performance through significant retained equity while permitting limited monetization under a structured plan.

Corporate Governance Expert

TL;DR: Transactions were executed under a disclosed 10b5-1 plan and include standard option vesting disclosures; governance appears compliant and transparent.

The Form 4 discloses the 10b5-1 plan date (12/05/2024) and provides detailed vesting schedules for RSUs and options, including the February 26, 2024 option grant and vesting through 2028. Ownership is reported clearly with direct and indirect holdings (Areth and Hariden LLCs) identified. The filing includes necessary explanatory footnotes and a dated signature, indicating procedural adherence to Section 16 reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		M		15,000(1)	A	$5.4	2,046,850	D
Common Stock	09/15/2025		S		15,000(1)	D	$16.13(2)	2,031,850	D
Common Stock	09/15/2025		S		6,000(1)	D	$16.13(2)	2,025,850(3)(4)(5)	D
Common Stock								1,143,426	I	See Footnote(6)
Common Stock								580,957	I	See Footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.4	09/15/2025		M			15,000(1)	(8)	02/26/2034	Common Stock	15,000	$0	765,950	D

Explanation of Responses:

1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

2. The price reported in Column 4 is the price at which the shares were sold.

3. Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

5. (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 993,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

6. These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

7. These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.

8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ADMA insider Adam Grossman report on Form 4 dated 09/15/2025?

The filing reports an option exercise to acquire 15,000 shares at $5.40 and sales of 15,000 and 6,000 shares at $16.13, executed under a Rule 10b5-1 plan.

How many ADMA shares does Adam Grossman beneficially own after the reported transactions?

After the transactions he directly owned 2,025,850 shares and indirectly controlled 1,724,383 shares through Areth, LLC and Hariden, LLC.

Were the trades executed under a pre-existing trading plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 5, 2024, as disclosed in the filing.

What equity awards and vesting schedules does the Form 4 disclose?

The filing details unvested RSUs totaling 1,033,966 from grants in 2022–2025 and an option granted 02/26/2024 that vests through 02/26/2028.

Who signed the Form 4 for Adam Grossman and when was it filed?

The Form 4 was signed by Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact on 09/16/2025.